A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...
The top 5 most-read dermatology content of 2025 on AJMC.com included innovative advances from artificial intelligence ...
The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced ...
Please provide your email address to receive an email when new articles are posted on . If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid in the U.S. The ...
DEAR DR. ROACH: I have had an autoimmune disease called bullous pemphigoid for the past four years. I originally was treated with prednisone therapy for over a year, which was then tapered and changed ...
Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...
BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions TARRYTOWN, N.Y. and ...
Clinical measurements of skin-related quality of life (SRQL) may aid in detecting critical disease severity information. Skin-related quality of life (SRQL) may be associated with flare-ups in ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with bullous pemphigoid treated with IL-2 had ...
Patients with cancer often require specialised care at centres located far from their residence. During the COVID-19 pandemic, telemedicine has rapidly gained ground as a way to ease system pressures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback